Safety of rasagiline for the treatment of Parkinson's disease

Author： Perez-Lloret Santiago Rascol Olivier

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.10, Iss.4, 2011-07, pp. : 633-643

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spotlight on Rasagiline in Parkinson's Disease

By Oldfield Vicki Keating Gillian M. Perry Caroline M.

CNS Drugs, Vol. 22, Iss. 1, 2008-01 ,pp. : 83-86

Adis International

Access to resources Recommend Favorite

Rasagiline: A Review of its Use in the Treatment of Idiopathic Parkinson's Disease

By Hoy Sheridan M. Keating Gillian M.

Drugs, Vol. 72, Iss. 5, 2012-03 ,pp. : 643-669

Adis International

Access to resources Recommend Favorite

Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease

By Solís-García del Pozo Julián Mínguez-Mínguez Sara

Expert Opinion on Drug Safety, Vol. 12, Iss. 4, 2013-07 ,pp. : 479-486

Informa Healthcare

Access to resources Recommend Favorite

Rasagiline in the pharmacotherapy of Parkinson’s disease – a review

By Rascol Olivier

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 12, 2005-10 ,pp. : 2061-2075

Informa Healthcare

Access to resources Recommend Favorite

Rasagiline monotherapy beneficial in early Parkinson's disease

Inpharma, Vol. 1, Iss. 1373, 2003-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite